Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23134784 | 0.85 | ALDH1A1 (0.36) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL24239497 | 0.81 | ALDH1A1 (0.50) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL23682306 | 0.78 | — | — | |
| SCHEMBL21305536 | 0.74 | ALDH1A1 (0.34) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL23685528 | 0.74 | ALDH1A1 (0.30) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL19871091 | 0.71 | ALDH1A1 (0.64) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL21305471 | 0.71 | ALDH1A1 (0.64) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL23685572 | 0.71 | — | — | |
| SCHEMBL19871067 | 0.64 | ALDH1A1 (0.38) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL23682258 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220359-A1 | Compositions and Methods for Treating Retinal Degradation | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220359-A1 | Compositions and Methods for Treating Retinal Degradation | POLRMT, TXNRD2, RNASE1 | ALDH1A1 1424/4885LMNA 50/4885ALB 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.